(Reuters) -Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage ...

Doctors and scientists who spoke to HuffPost are worried for a multitude of reasons and want you to know that this will ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing ...

VANGUARD has selected five companies for up to $200,000 in non-dilutive funding contracts and 10 companies for the 2025 ...

Reports Q2 revenue $2.7M vs. $57,000 last year. “Traws has made good progress this year towards our goal of bringing our antiviral candidates to ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ...

ALLSCHWIL, Switzerland I August 14, 2025 I Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting ...

The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to ...

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

It ain’t what you don’t know that gets you into trouble. It’s what you know for sure that just ain’t so.” Mark Twain’s quip ...